Preservation Park (Nile Hall)
1233 Preservation Park Way
Oakland CA, 94612
Boston Marriott Cambridge
Cambridge, MA, 02142
The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.
CTAF will convene to review ICER's report on CGRP inhibitors for prevention of migraine headaches.
The New England CEPAC will convene to review ICER's condition update on therapies for plaque psoriasis. During this meeting, the Council will also review a report on elagolix for endometriosis.
The New England CEPAC will review ICER's report on elagolix for endometriosis.
The Midwest CEPAC will deliberate and vote on ICER's report on threatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council will also review a report on therapies for prostate cancer during this meeting.
The Midwest CEPAC will deliberate and vote on evidence presented in ICER's report on anti-androgen drugs for high risk prostate cancer. During this meeting, the Council will also discuss ICER's review of treatments for amyloidosis .
The Midwest CEPAC convened to deliberate on ICER's report on voretigene neparvovec (LuxturnaTM, Spark Therapeutics).
The New England CEPAC convened to review ICER's evidence report assessing the clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder related to prolonged use of antipsychotic medications.
CTAF reviewed ICER's report on the comparative clinical effectiveness and value of certain cognitive and mind-body interventions for chronic low back and neck pain.
The Midwest CEPAC convened to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.
ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.
The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.
ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.
The Midwest CEPAC convened in May 2017 to discuss ICER's report on dupilumab and crisaborole for atopic dermatitis.
The New England CEPAC convened on March 24, 2017 to discuss ICER's report on treatments for rheumatoid arthritis.
The California Technology Assessment Forum convened to discuss ICER's report on treatments for Multiple Sclerosis.